Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.

Joshua M Donaldson, Marjilla Seddiq,Michael J Fusco, Shyamli Singla, Gulsum E Pamuk, Rosa J Lee-Alonso,Bronwyn D Mixter,Kirsten B Goldberg,Laleh Amiri-Kordestani,R Angelo de Claro,Nicole Drezner,Nicole J Gormley,Bindu Kanapuru,Steven J Lemery,Lola A Fashoyin-Aje, Nicholas C Richardson,Harpreet Singh,Daniel L Suzman,Marc R Theoret,Paul G Kluetz,Richard Pazdur

Cancer discovery（2023）

引用 0|浏览3

暂无评分

摘要

SUMMARY:Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要